Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:JBIO NASDAQ:PURR NASDAQ:SANA NASDAQ:TKNO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJBIOJade Biosciences$21.34+0.2%$20.68$6.67▼$28.00$1.05B1.431.29 million shs1.22 million shsPURRHyperliquid Strategies$7.36+2.8%$8.24$3.01▼$11.62$1.03B1.6612.86 million shs9.90 million shsSANASana Biotechnology$3.57-1.9%$3.28$2.61▼$6.55$1.01B2.133.46 million shs2.02 million shsTKNOAlpha Teknova$5.41$4.72$1.91▼$6.68$290.05M0.62226,381 shs209,587 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJBIOJade Biosciences+0.19%-4.94%+39.11%+10.80%+137.11%PURRHyperliquid Strategies+2.79%-10.02%-15.40%+13.06%+735,999,900.00%SANASana Biotechnology-1.92%-13.35%+33.21%+3.78%-15.40%TKNOAlpha Teknova0.00%-0.37%+28.81%+97.45%+20.49%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJBIOJade Biosciences$21.34+0.2%$20.68$6.67▼$28.00$1.05B1.431.29 million shs1.22 million shsPURRHyperliquid Strategies$7.36+2.8%$8.24$3.01▼$11.62$1.03B1.6612.86 million shs9.90 million shsSANASana Biotechnology$3.57-1.9%$3.28$2.61▼$6.55$1.01B2.133.46 million shs2.02 million shsTKNOAlpha Teknova$5.41$4.72$1.91▼$6.68$290.05M0.62226,381 shs209,587 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJBIOJade Biosciences+0.19%-4.94%+39.11%+10.80%+137.11%PURRHyperliquid Strategies+2.79%-10.02%-15.40%+13.06%+735,999,900.00%SANASana Biotechnology-1.92%-13.35%+33.21%+3.78%-15.40%TKNOAlpha Teknova0.00%-0.37%+28.81%+97.45%+20.49%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceJBIOJade Biosciences 2.90Moderate Buy$51.57141.67% UpsidePURRHyperliquid Strategies 2.50Moderate Buy$12.7272.78% UpsideSANASana Biotechnology 2.67Moderate Buy$9.50166.11% UpsideTKNOAlpha Teknova 2.33Hold$8.0047.87% UpsideCurrent Analyst Ratings BreakdownLatest TKNO, PURR, JBIO, and SANA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2026PURRHyperliquid Strategies Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$8.00 ➝ $18.406/16/2026JBIOJade Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)6/15/2026JBIOJade Biosciences UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.006/15/2026JBIOJade Biosciences UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.006/12/2026PURRHyperliquid Strategies Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.756/3/2026PURRHyperliquid Strategies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)6/2/2026JBIOJade Biosciences Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$55.006/2/2026JBIOJade Biosciences GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$47.006/2/2026JBIOJade Biosciences WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$34.00 ➝ $45.006/1/2026JBIOJade Biosciences Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/1/2026JBIOJade Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D)(Data available from 7/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookJBIOJade BiosciencesN/AN/AN/AN/A$6.74 per shareN/APURRHyperliquid Strategies$1M1,063.15N/AN/A$1.52 per share4.84SANASana BiotechnologyN/AN/AN/AN/A$0.60 per shareN/ATKNOAlpha Teknova$40.52M7.16N/AN/A$1.28 per share4.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateJBIOJade Biosciences-$127.41M-$2.02N/AN/AN/AN/A-51.34%-47.32%N/APURRHyperliquid Strategies-$16.01M-$7.37N/AN/AN/AN/A-56.04%-52.22%N/ASANASana Biotechnology-$244.17M-$0.93N/AN/AN/AN/A-108.01%-40.68%8/10/2026 (Estimated)TKNOAlpha Teknova-$17.26M-$0.32N/AN/AN/A-41.07%-24.32%-16.34%8/5/2026 (Estimated)Latest TKNO, PURR, JBIO, and SANA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/10/2026Q2 2026SANASana Biotechnology-$0.15N/AN/AN/AN/AN/A8/5/2026Q2 2026TKNOAlpha Teknova-$0.0833N/AN/AN/A$10.91 millionN/A5/11/2026Q1 2026SANASana Biotechnology-$0.15-$0.14+$0.01-$0.17N/AN/A5/7/2026Q1 2026JBIOJade Biosciences-$0.52-$0.57-$0.05-$0.57N/AN/A5/7/2026Q3 2026PURRHyperliquid StrategiesN/A$1.01N/A$1.01N/A$2.63 million5/6/2026Q1 2026TKNOAlpha Teknova-$0.0926-$0.08+$0.0126-$0.08$10.23 million$11.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthJBIOJade BiosciencesN/AN/AN/AN/AN/APURRHyperliquid StrategiesN/AN/AN/AN/AN/ASANASana BiotechnologyN/AN/AN/AN/AN/ATKNOAlpha TeknovaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioJBIOJade BiosciencesN/A14.2914.29PURRHyperliquid StrategiesN/A18.2318.22SANASana BiotechnologyN/A1.291.29TKNOAlpha Teknova0.204.593.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipJBIOJade BiosciencesN/APURRHyperliquid Strategies9.45%SANASana Biotechnology88.23%TKNOAlpha Teknova13.81%Insider OwnershipCompanyInsider OwnershipJBIOJade Biosciences23.06%PURRHyperliquid Strategies8.48%SANASana Biotechnology25.40%TKNOAlpha Teknova12.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableJBIOJade Biosciences2049.36 million37.98 millionN/APURRHyperliquid StrategiesN/A144.45 million132.20 millionN/ASANASana Biotechnology380278.29 million207.61 millionOptionableTKNOAlpha Teknova24053.61 million46.91 millionNot OptionableTKNO, PURR, JBIO, and SANA HeadlinesRecent News About These CompaniesAnalysts Offer Insights on Healthcare Companies: Alpha Teknova (TKNO), Arcus Biosciences (RCUS) and Tenaya Therapeutics (TNYA)June 4, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Alpha Teknova (TKNO) and REPRO-MED Systems (KRMD)May 9, 2026 | theglobeandmail.comAlpha Teknova, Inc. (NASDAQ:TKNO) Just Released Its First-Quarter Results And Analysts Are Updating Their EstimatesMay 9, 2026 | finance.yahoo.comAlpha Teknova, Inc. (TKNO) Q1 2026 Earnings Call TranscriptMay 8, 2026 | seekingalpha.comAlpha Teknova Charts Cautious Path to 2027 GrowthMay 7, 2026 | tipranks.comAlpha Teknova (TKNO) Q1 2026 Earnings TranscriptMay 6, 2026 | finance.yahoo.comTeknova Reports First Quarter 2026 Financial ResultsMay 6, 2026 | globenewswire.comTeknova to Report First Quarter 2026 Financial Results on May 6, 2026April 22, 2026 | globenewswire.comFavourable Signals For Alpha Teknova: Numerous Insiders Acquired StockMarch 30, 2026 | finance.yahoo.comAlpha Teknova (NASDAQ:TKNO) CEO Acquires $55,900.00 in StockMarch 10, 2026 | insidertrades.comTeknova outlines 20%-25% long-term revenue growth target while investing $2M annually in commercial capabilitiesFebruary 27, 2026 | seekingalpha.comAlpha Teknova Inc (TKNO) Q4 2025 Earnings Call Highlights: Navigating Growth Amid ChallengesFebruary 27, 2026 | finance.yahoo.comAlpha Teknova, Inc. (TKNO) Q4 2025 Earnings Call TranscriptFebruary 26, 2026 | seekingalpha.comTeknova Reports Fourth Quarter and Full Year 2025 Financial ResultsFebruary 26, 2026 | globenewswire.comEarnings To Watch: Alpha Teknova Inc (TKNO) Reports Q4 2025 ResultFebruary 25, 2026 | finance.yahoo.comAlpha Teknova (TKNO): Investors are Waiting for Leading Indicators to Drive SalesFebruary 20, 2026 | insidermonkey.comTeknova to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026February 5, 2026 | globenewswire.comWhy Alpha Teknova, Inc.’s (TKNO) Stock Is Down 13.01%December 22, 2025 | aaii.comAAnalysts Offer Insights on Healthcare Companies: Alpha Teknova (TKNO), Voyager Therapeutics (VYGR) and Terns Pharmaceuticals (TERN)November 13, 2025 | theglobeandmail.comAlpha Teknova, Inc. (NASDAQ:TKNO) Analysts Are Pretty Bullish On The Stock After Recent ResultsNovember 8, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTKNO, PURR, JBIO, and SANA Company DescriptionsJade Biosciences NASDAQ:JBIO$21.34 +0.04 (+0.19%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$22.00 +0.66 (+3.09%) As of 05:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Hyperliquid Strategies NASDAQ:PURR$7.36 +0.20 (+2.79%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$7.60 +0.23 (+3.19%) As of 06:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Hyperliquid Strategies Inc is a digital asset treasury company whose primary focus is to maximize shareholder value through accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. Hyperliquid Strategies Inc, formerly known as Sonnet BioTherapeutics Holdings Inc., is based in NEW YORK.Sana Biotechnology NASDAQ:SANA$3.57 -0.07 (-1.92%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$3.64 +0.07 (+1.96%) As of 05:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.Alpha Teknova NASDAQ:TKNO$5.41 0.00 (0.00%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$5.30 -0.11 (-2.01%) As of 07/14/2026 06:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet 3 Overlooked Energy ETFs Delivering Strong Returns and Income 3 Space Stocks That Could Outshine SpaceX After Its IPO 3 Energy Stocks Racing to Fix AI's Power Problem JPMorgan’s Q2 Strength Gives the Stock Rally New Support No Space For Panic: T-Mobile Shrugs Off The Starlink Threat Prepare for the Next Wave of Factory Automation With These 3 Standout Names Wedbush Pounds the Table—Buy Sandisk Before August 5 Earnings Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
